Fortaco Group to be Acquired by One Equity Partners
8.7.2022 14:00:00 EEST | Business Wire | Press release
Funds managed by CapMan Buyout have agreed to sell their holdings in Fortaco Group, the leading strategic partner to the heavy off-highway equipment and marine industries offering technology, vehicle cabins, steel fabrications, and assemblies to global OEMs, to private equity firm One Equity Partners.
As the new owner, One Equity Partners will empower the further development of the current and new offerings of Fortaco, including areas to strengthen value creation to customers and to provide the means for further international expansion.
“We are very honored to become a member of the One Equity Partners family. I want to express my sincere thanks to all our global customers, business partners, and the Fortaco team for the highly qualified performance we reached together. With One Equity Partners, we are looking forward to realizing the full potential of Fortaco as the leading business partner of technology, vehicle cabins, steel fabrications and assemblies. In addition, I want to thank CapMan as the owner and the Board of Directors for their support and trust,” says Lars Hellberg, President & CEO of Fortaco Group.
“We look forward to partnering with Fortaco CEO Lars Hellberg and his team, applying our industrial sector expertise to support Fortaco in broadening and deepening its offerings in current markets and expanding into new end markets where we believe the Company is well-positioned for success,” said Johann-Melchior von Peter, Senior Managing Director at One Equity Partners. “We see ample opportunity for Fortaco to leverage its global manufacturing and sourcing footprint and extend its value to clients by helping them improve their operational efficiency,” adds Marc Lindhorst, Principal at One Equity Partners.
Under the ownership of CapMan, Fortaco has grown and become a market-leading, premium industrial company. Fortaco has factories across seven European countries, in addition to a joint venture with Tata AutoComp in India. Fortaco also has a large portfolio of global customers in different industry segments, and the company’s turnover and profitability have developed very favorably in recent years.
“CapMan was one of the initiators in the formation of Fortaco Group ten years ago. We have provided continuous strategic support over the company’s many development phases towards the market leader it is today with ambitious growth prospects. I would like to thank Fortaco’s management team and employees for excellent co-operation over the years. The company is now well-positioned to continue its growth journey with One Equity Partners as the new owner,” says Anders Björkell, partner at CapMan Buyout.
Closing of the transaction is expected in the second half of 2022 and is subject to regulatory approvals and customary closing conditions.
Fortaco
Fortaco is the leading brand-independent strategic partner to the heavy off-highway equipment and marine industries offering technology, vehicle cabins, steel fabrications and assemblies. Fortaco Group has operations in multiple European and Asian business sites and technology hubs, which are supporting the global customers.
One Equity Partners
One Equity Partners is a middle market private equity firm focused on transformative combinations within the industrial, healthcare and technology sectors in North America and Europe. The firm was founded in 2001 and spun out of JP Morgan in 2015 to become an independent partnership. One Equity Partners has completed more than 300 transactions worldwide with offices in New York, Chicago, Frankfurt and Amsterdam.
CapMan
CapMan is a leading Nordic private assets manager and investor with an active approach to value creation. As one of the private equity pioneers in the Nordics they have built value in unlisted businesses, real estate, and infrastructure for over three decades. With over €4.7 billion in assets under management, their objective is to provide attractive returns and innovative solutions to investors.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220708005059/en/
Contact information
For more information
Lars Hellberg
+358 40 572 9488
lars.hellberg@fortacogroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom